Anaphylaxis Clinical Trial
Official title:
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers: Does Dose Matter?
Food allergy affects up to 2% of adults and 8% of children in the United Kingdom (UK), and is a major public health issue. It is the commonest cause of life-threatening allergic reactions (anaphylaxis), which can be fatal. Adrenaline (epinephrine) auto-injector (AAI) devices are the first-line treatment for anaphylaxis, yet in a UK survey, over 80% of 245 teenagers experiencing anaphylaxis did not use their AAI. Delays in, or lack of adrenaline (epinephrine) administration during anaphylaxis are risk factors for fatal anaphylaxis. In 2010, a coroner's investigation into the death of a food-allergic teenager in the UK raised several questions around AAI safety and efficacy, since the teenager died despite administering her auto-injector device. This prompted a review by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2014 into the clinical and quality considerations of AAIs. Two recommendations which came from the review was that companies 'should be encouraged to develop a 0.5mg [dose] AAI.' In the UK currently only Emerade, one of the three companies selling AAIs, manufactures a 0.5mg (500mcg) version. Emerade also has a longer needle length (23mm) compared to other AAIs (typically 15mm). The investigators plan to formally assess the pharmacokinetics (PK) and pharmacodynamics (PD) of self-injection with intramuscular adrenaline (epinephrine) in teenagers at risk of anaphylaxis due to food allergy, and have been prescribed AAI. 1. The investigators will compare self-injection with 300mcg vs 500mcg in teenagers of body weight >40kg. In a 40kg person, an adrenaline dose of 300mcg results in an effective UNDER-dosing of 30% by body weight. 2. The investigators will also assess the impact of needle length on injection, by comparing two different devices, both of which deliver 300mcg, but one via a 15mm needle and the other with a 23mm needle.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04475003 -
Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
|
||
| Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
| Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
| Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
| Active, not recruiting |
NCT03953482 -
Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
|
||
| Recruiting |
NCT05112367 -
Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
|
||
| Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
| Completed |
NCT04696822 -
Bioavailability of Nasal Epinephrine
|
Phase 1 | |
| Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
| Completed |
NCT02854969 -
Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device
|
N/A | |
| Completed |
NCT03282929 -
Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)
|
Phase 1 | |
| Recruiting |
NCT01326741 -
Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis
|
N/A | |
| Recruiting |
NCT06445374 -
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges
|
Phase 1 | |
| Completed |
NCT01217138 -
Make up for the Epinephrine Autoinjector
|
Phase 4 | |
| Completed |
NCT02424136 -
PEAnut Anaphylaxis Predictors
|
N/A | |
| Completed |
NCT01432522 -
A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine
|
N/A | |
| Completed |
NCT02028065 -
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
|
Phase 1 | |
| Active, not recruiting |
NCT01247415 -
Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
|
N/A | |
| Completed |
NCT00868842 -
Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis
|
N/A | |
| Completed |
NCT04290507 -
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
|